Abstract
New biologic therapies focused primarily on cytokine pathways, some targeting T cell-mediated immune responses, are being developed for the treatment of psoriasis. Siplizumab is a humanized anti-CD2 monoclonal antibody that interferes with costimulation necessary for T cell activation and proliferation. We assessed the biological activity, serum concentrations, and pharmacodynamic effects of siplizumab in patients with plaque psoriasis. Two multicenter, phase II randomized, double-blind, placebo-controlled studies were conducted: one study randomized 124 patients to one of two intravenous (IV) doses (0.012 and 0.04 mg/kg) of siplizumab, given every 2 weeks × 8 doses; the other study randomized 420 patients to one of three subcutaneous (SC) dose regimens of siplizumab given weekly (5 mg for 12 weeks, 5 mg for 6 weeks, and 7 mg for 4 weeks) or placebo for 12 weeks. Adults with plaque psoriasis involving ≥10% of the body surface area and who were not receiving psoriasis therapy were eligible. Treatment with siplizumab resulted in reductions in psoriasis severity, but most of the effects were not statistically significant compared with placebo. Statistically significant differences among IV siplizumab-treated and placebo groups were observed at study day 28, with greater psoriasis area and severity index (PASI) score reductions from baseline in the siplizumab groups. The difference in PASI50 response rates between the 0.04 mg/kg siplizumab and placebo groups was also statistically significant at day 28. A trend toward clinical improvement was observed in SC siplizumab-treated groups. Significant reductions in circulating absolute lymphocyte counts and CD2+ (CD3+, CD8+, and CD16+/56+), but not CD2− (CD19+ and CD14+), lymphocyte populations were observed. These changes were not accompanied by concomitant reductions in infiltrating CD3+ lymphocytes in psoriatic lesions, epidermal thickness, or keratin 16 (K16) and intercellular adhesion molecule (ICAM) expression. The effect of siplizumab did not differentially affect CD45RO+ and CD45RA+ lymphocytes. Low or undetectable mean trough serum concentrations of siplizumab following IV or SC treatment were observed. Pharmacokinetic data coupled with higher-than-expected placebo clinical response rates may partly explain siplizumab’s marginal clinical activity. Higher doses of siplizumab may be required to detect significant improvements in psoriasis; however, further development of this agent was not planned.
Similar content being viewed by others
References
Bierer BE, Hahn WC (1993) T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2. Semin Immunol 5:249–261. doi:10.1006/smim.1993.1029
Branco L, Barren P, Mao SY, Pfarr D, Kaplan R, Postema C, Langermann S, Koenig S, Johnson S (1999) Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 68:1588–1596. doi:10.1097/00007890-199911270-00026
Ellis CN, Krueger GG, Alefacept Clinical Study Group (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248–255. doi:10.1056/NEJM200107263450403
Ellis CN, Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA, Avandia Psoriasis Study Group (2007) Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 8:93–102. doi:10.2165/00128071-200708020-00005
Gniadecki R, Calverley MJ (2002) Emerging drugs in psoriasis. Expert Opin Emerg Drugs 7:69–90. doi:10.1517/14728214.7.1.69
Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55:598–606. doi:10.1016/j.jaad.2006.05.027
Koo J (1996) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14:485–496. doi:10.1016/S0733-8635(05)70376-4
Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, Alefacept Clinical Study Group (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821–833. doi:10.1067/mjd.2002.127247
Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, CNTO 1275 Psoriasis Study Group (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356:580–592. doi:10.1056/NEJMoa062382
Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1–23. doi:10.1067/mjd.2002.120568
Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, Alefacept Clinical Study Group (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719–727. doi:10.1001/archderm.139.6.719
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826–850. doi:10.1016/j.jaad.2008.02.039
Nast A et al (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299:111–138. doi:10.1007/s00403-007-0744-y
Papp K et al (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45:665–674. doi:10.1067/mjd.2001.117850
Papp KA (2006) The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 298:7–15. doi:10.1007/s00403-006-0660-6
Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367–1374. doi:10.1016/S0140-6736(05)67566-6
Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899–1912. doi:10.1056/NEJMra041320
Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, British Association of Dermatologists (2005) British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153:486–497. doi:10.1111/j.1365-2133.2005.06893.x
Spuls PI, Witkamp L, Bossuyt PM, Bos JD (2004) The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol 140:338–344 (discussion 344). doi:10.1001/archderm.140.3.338
Sterry W et al (2004) Biological therapies in the systemic management of psoriasis: International consensus conference. Br J Dermatol 151:3–17. doi:10.1111/j.1365-2133.2004.06070.x
Thomas VD, Yang FC, Kvedar JC (2005) Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 53:346–351. doi:10.1016/j.jaad.2005.04.011
Torti DC, Feldman SR (2007) Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 57:1059–1068. doi:10.1016/j.jaad.2007.07.016
Vena GA, Cassano N (2006) Emerging drugs for psoriasis. Expert Opin Emerg Drugs 11:567–596. doi:10.1517/14728214.11.4.567
Acknowledgments
These studies were funded by MedImmune, LLC, Gaithersburg, MD, USA. The authors thank Christine A. Dingivan, MD, for overseeing the studies. The authors also thank Miriam Gitler, PhD, for her medical writing and editorial assistance in the preparation of this manuscript. Drs. Papp, Bissonnette, Langley, Toth, and Matheson received research funding from MedImmune, LLC. Ms. Hultquist, and Drs. Geba and White are employees of MedImmune, LLC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bissonnette, R., Langley, R.G., Papp, K. et al. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch Dermatol Res 301, 429–442 (2009). https://doi.org/10.1007/s00403-009-0961-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-009-0961-7